<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34260979</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-3064</ISSN><JournalIssue CitedMedium="Internet"><Volume>186</Volume><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Respiratory medicine</Title><ISOAbbreviation>Respir Med</ISOAbbreviation></Journal><ArticleTitle>Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>106536</StartPage><MedlinePgn>106536</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rmed.2021.106536</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0954-6111(21)00242-0</ELocationID><Abstract><AbstractText Label="UNLABELLED">Treatment with Dextromethorphan/Quinidine (DM/Q) has demonstrated benefit on pseudobulbar affect and bulbar function in amyotrophic lateral sclerosis (ALS). The aim of this study was to assess whether DM/Q could provide long-term improvement in bulbar function and thereby prolong noninvasive respiratory management in ALS.</AbstractText><AbstractText Label="MATERIALS AND METHODS">This prospective, case-cohort study, recruited ALS patients with bulbar dysfunction. Subjects included were compared with cross-matched historical controls. Cases received DM/Q (20/10&#xa0;mg twice daily) during one-year follow-up; bulbar dysfunction was evaluated with the Norris scale bulbar subscore (NBS) and bulbar subscale of AlSFRS-R (ALSFRSb).</AbstractText><AbstractText Label="RESULTS">In total, 21 cases and 20 controls were enrolled, of whom noninvasive respiratory muscle assistance failed in 6 (28.5%) patients in the DM/Q group, compared with 4 patients (20.0%) in the control group (p&#xa0;=&#xa0;0.645). Time from study onset to failure of respiratory muscle aids was 5.50&#xa0;+&#xa0;1.31 months in the DM/Q group and 5.20&#xa0;+&#xa0;1.15 months in the control group (p&#xa0;=&#xa0;0.663). The adjusted OR for the effect of treatment on failure of noninvasive respiratory muscle aids was 2.12 (95%CI 0.23-33.79, p&#xa0;=&#xa0;0.592). In the DM/Q group an impairment in scores was found in NBS (F&#xa0;=&#xa0;19.26, p&#xa0;=&#xa0;0.000) and ALSFRS-Rb (F&#xa0;=&#xa0;12.71, p&#xa0;=&#xa0;0.001) across different months of the study.</AbstractText><AbstractText Label="CONCLUSION">Treatment with DM/Q in ALS is unable to prolong noninvasive respiratory management, and moreover, has no effect on long-term deterioration of bulbar function. Notwithstanding the results on bulbar function, DM/Q was found to improve pseudobulbar affect during one-year follow-up.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sancho</LastName><ForeName>Jesus</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital Cl&#xed;nico Universitario, Valencia, Spain; Research Group for Respiratory Problems in Neuromuscular Diseases, INCLIVA Health Research Institute, Spain. Electronic address: jesus.sancho@uv.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer</LastName><ForeName>Santos</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital Cl&#xed;nico Universitario, Valencia, Spain; Research Group for Respiratory Problems in Neuromuscular Diseases, INCLIVA Health Research Institute, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bur&#xe9;s</LastName><ForeName>Enric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital Cl&#xed;nico Universitario, Valencia, Spain; Research Group for Respiratory Problems in Neuromuscular Diseases, INCLIVA Health Research Institute, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luis D&#xed;az</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital Cl&#xed;nico Universitario, Valencia, Spain; Research Group for Respiratory Problems in Neuromuscular Diseases, INCLIVA Health Research Institute, Spain; International University of Valencia(VIU), Spain; Airliquide Healthcare Group, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrecilla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Hospital Cl&#xed;nico Universitario, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Signes-Costa</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital Cl&#xed;nico Universitario, Valencia, Spain; Research Group for Respiratory Problems in Neuromuscular Diseases, INCLIVA Health Research Institute, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Servera</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Research Group for Respiratory Problems in Neuromuscular Diseases, INCLIVA Health Research Institute, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Respir Med</MedlineTA><NlmUniqueID>8908438</NlmUniqueID><ISSNLinking>0954-6111</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7355X3ROTS</RegistryNumber><NameOfSubstance UI="D003915">Dextromethorphan</NameOfSubstance></Chemical><Chemical><RegistryNumber>ITX08688JL</RegistryNumber><NameOfSubstance UI="D011802">Quinidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003915" MajorTopicYN="N">Dextromethorphan</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011802" MajorTopicYN="N">Quinidine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Assisted coughing</Keyword><Keyword MajorTopicYN="N">Bulbar dysfunction</Keyword><Keyword MajorTopicYN="N">Dextromethorphan/quinidine</Keyword><Keyword MajorTopicYN="N">Noninvasive ventilation</Keyword><Keyword MajorTopicYN="N">Pseudobulbar affect</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>14</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34260979</ArticleId><ArticleId IdType="doi">10.1016/j.rmed.2021.106536</ArticleId><ArticleId IdType="pii">S0954-6111(21)00242-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>